MindBio Therapeutics (XCNQ:MBIO) Machinery, Furniture, Equipment : C$0.00 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Machinery, Furniture, Equipment?

MindBio Therapeutics's Machinery, Furniture, Equipment for the quarter that ended in Mar. 2024 was C$0.00 Mil.

MindBio Therapeutics Machinery, Furniture, Equipment Historical Data

The historical data trend for MindBio Therapeutics's Machinery, Furniture, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Machinery, Furniture, Equipment Chart

MindBio Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Machinery, Furniture, Equipment

MindBio Therapeutics Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Machinery, Furniture, Equipment	Get a 7-Day Free Trial					-	-	-	-	-

MindBio Therapeutics Machinery, Furniture, Equipment Calculation

Machinery, Furniture, Equipment represents those fixed assets specifically dealing with tools, equipment and office furniture.

MindBio Therapeutics (XCNQ:MBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Machinery, Furniture, Equipment

Comparable Companies

Traded in Other Exchanges

WF6:Germany

Address

91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000

Website

https://www.mindbiotherapeutics.com

MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.